DecisionView (San Francisco, CA) announced today that its Web-based enrollment application, StudyOptimizer, will now be available as Software-as-a-Service (SAS). In addition to faster deployment, the pay-as-you-go version will deliver a lower cost of ownership, says the company.
"We realized the importance of accelerating the adoption of our solution, so that customers could implement corrective actions in their enrollment processes as quickly as possible," said Jim Scullion, Chief Executive Officer of DecisionView. "With the launch of this new offering, companies can leverage the planning and forecasting capabilities of StudyOptimizer in a shorter time frame, even on a single trial."
The SAS model will be hosted in a SAS70 certified infrastructure and is available now.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.